Alligator Bioscience AB (LTS:0RK9) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RK9 Alligator Bioscience AB LTS:0RK9
42 GF Score
Price kr0.19
GF Value kr0.01
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alligator Bioscience AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0RK9 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alligator Bioscience AB Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Short Interest falls into.


LTS:0RK9
42GF Score
Alligator Bioscience AB LTS:0RK9
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alligator Bioscience AB (LTS:0RK9) Overvalued in 2026?

Based on GuruFocus' analysis, Alligator Bioscience AB stock appears to be overvalued. The current stock price of kr0.19 is trading 1792% above its estimated GF Value™ of kr0.01. GuruFocus considers Alligator Bioscience AB to be Significantly Overvalued.

Key valuation signals for LTS:0RK9:

  • Short Interest:
  • GF Value™: kr0.01 vs. price of kr0.19 (1792% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the LTS:0RK9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alligator Bioscience AB Business Description

Other Exchanges ATORX:Sweden7AL0:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
42GF Score

Get the complete analysis for LTS:0RK9

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.19
Price
kr0.01
GF Value